STORE Capital Corp
Change company Symbol lookup
Select an option...
STOR STORE Capital Corp
SWCH Switch Inc
SWKS Skyworks Solutions Inc
MSB Mesabi Trust
ESS Essex Property Trust Inc
WRAP Wrap Technologies Inc
GOOG Alphabet Inc
MMMB MamaMancini's Holdings Inc
RXT Rackspace Technology Inc
RKT Rocket Companies Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Blend
Company profile

STORE Capital Corporation is an internally managed net-lease real estate investment trust. The Company is engaged in the acquisition, investment and management of single tenant operational real estate (STORE) properties. As of December 31, 2016, the Company owned a portfolio that consisted of investments in 1,660 property locations operated by 360 customers across 48 states. Its customers operate across a range of industries within the service, retail and manufacturing sectors of the United States economy, with restaurants, early childhood education centers, movie theaters, health clubs and furniture stores. The Company's portfolio includes investments in approximately 1,330 property locations operated by over 300 customers across approximately 50 states. The Company provides real estate financing solutions principally to businesses that own STORE properties and operate within the broad-based service, retail and industrial sectors of the United States economy.

Postmarket

Last Trade
Delayed
$30.85
-0.01 (-0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$30.86
Day's Change
-0.13 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
30.96
Day's Low
30.27
Volume
(Light)
Volume:
1,622,430

10-day average volume:
2,246,953
1,622,430

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

12:30 pm ET November 19, 2020 (BusinessWire) Print

The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN) on behalf of investors concerning the Company's possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On November 9, 2020, after the market closed, Supernus disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its new drug application ("NDA") for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old. According to the CRL, the NDA "is not ready for approval in its present form." Among other things, "[t]he primary issue cited in the SPN-812 CRL relates to the Company's in-house laboratory that conducts analytical testing, which recently moved to a new location."

On this news, Supernus's stock price fell $3.88 per share, or approximately 16%, to close at $21.08 per share on November 10, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Supernus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005522/en/

SOURCE: The Law Offices of Frank R. Cruz">

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com 
www.frankcruzlaw.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.